Characterizing academic performance in pediatric acute lymphoblastic leukemia with population-based achievement tests.
cancer
cognition
education
leukemia
oncology
survivors
Journal
Cancer reports (Hoboken, N.J.)
ISSN: 2573-8348
Titre abrégé: Cancer Rep (Hoboken)
Pays: United States
ID NLM: 101747728
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
revised:
09
08
2021
received:
11
06
2021
accepted:
30
08
2021
pubmed:
2
10
2021
medline:
14
9
2022
entrez:
1
10
2021
Statut:
ppublish
Résumé
Recent shifts from radiation to chemotherapy-based treatment for acute lymphoblastic leukemia (ALL) have contributed to reduced long-term morbidity. Despite this, ALL survivors remain at increased risk for long-term cognitive impairments. To identify demographic and treatment factors associated with school performance in pediatric survivors of ALL. We collected standardized test scores for reading, math, and science obtained in a school setting from grades 3-11 in 63 ALL survivors (46.0% boys). Most participants were assessed across multiple grades (median number of grades n = 5, range 1-7), and 269 observations were considered in the analyses. Treatment exposures were extracted from medical records. Socio-economic status was estimated using participation in free/reduced lunch programs at school. Mixed effects linear regression models were conducted to determine factors associated with school performance. ALL survivors' scores were comparable to state norms on reading, math, and science performances. On multivariable analysis, participation in free/reduced lunch programs was significantly associated with lower reading scores (β = -12.52; 95% CI -22.26:-2.77, p = .01). Exposure to radiation during treatment was also associated with lower reading test scores (β = -30.81, 95% CI -52.00:-9.62, p = .01). No significant associations between demographics and treatment parameters were observed for math and science test scores. We utilized population-based achievement tests conducted from grades 3-11 to characterize school performance in ALL survivors. Our results imply that survivors with low socio-economic status and those exposed to radiation during treatment could benefit from early monitoring and intervention to maximize academic success.
Sections du résumé
BACKGROUND
Recent shifts from radiation to chemotherapy-based treatment for acute lymphoblastic leukemia (ALL) have contributed to reduced long-term morbidity. Despite this, ALL survivors remain at increased risk for long-term cognitive impairments.
AIM
To identify demographic and treatment factors associated with school performance in pediatric survivors of ALL.
METHODS
We collected standardized test scores for reading, math, and science obtained in a school setting from grades 3-11 in 63 ALL survivors (46.0% boys). Most participants were assessed across multiple grades (median number of grades n = 5, range 1-7), and 269 observations were considered in the analyses. Treatment exposures were extracted from medical records. Socio-economic status was estimated using participation in free/reduced lunch programs at school. Mixed effects linear regression models were conducted to determine factors associated with school performance.
RESULTS
ALL survivors' scores were comparable to state norms on reading, math, and science performances. On multivariable analysis, participation in free/reduced lunch programs was significantly associated with lower reading scores (β = -12.52; 95% CI -22.26:-2.77, p = .01). Exposure to radiation during treatment was also associated with lower reading test scores (β = -30.81, 95% CI -52.00:-9.62, p = .01). No significant associations between demographics and treatment parameters were observed for math and science test scores.
CONCLUSIONS
We utilized population-based achievement tests conducted from grades 3-11 to characterize school performance in ALL survivors. Our results imply that survivors with low socio-economic status and those exposed to radiation during treatment could benefit from early monitoring and intervention to maximize academic success.
Identifiants
pubmed: 34596316
doi: 10.1002/cnr2.1560
pmc: PMC9458490
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1560Subventions
Organisme : NICHD NIH HHS
ID : P50 HD103556
Pays : United States
Informations de copyright
© 2021 The Authors. Cancer Reports published by Wiley Periodicals LLC.
Références
J Clin Oncol. 2021 Jun 1;39(16):1775-1785
pubmed: 33886371
Pediatr Blood Cancer. 2016 Jan;63(1):133-8
pubmed: 26312396
Semin Hematol. 2013 Jul;50(3):185-96
pubmed: 23953334
Cancer Nurs. 2016 Jul-Aug;39(4):255-62
pubmed: 26166361
J Natl Cancer Inst. 2021 May 4;113(5):588-596
pubmed: 32882041
Pediatr Blood Cancer. 2013 Nov;60(11):1778-84
pubmed: 23775832
Pediatr Blood Cancer. 2021 Apr;68(4):e28913
pubmed: 33522102
J Clin Oncol. 2021 Jun 1;39(16):1705-1717
pubmed: 33886368
Clin Cancer Res. 2018 Dec 1;24(23):6040-6052
pubmed: 30054283
Crit Rev Oncol Hematol. 2020 Jan;145:102838
pubmed: 31786347
Neurosci Biobehav Rev. 2015 Jun;53:108-20
pubmed: 25857254
Lancet Psychiatry. 2016 Oct;3(10):965-972
pubmed: 27639661
J Clin Oncol. 2021 Jun 1;39(16):1813-1823
pubmed: 33886350
J Pharmacol Pharmacother. 2016 Apr-Jun;7(2):62-71
pubmed: 27440950
Cancer Rep (Hoboken). 2022 Sep;5(9):e1560
pubmed: 34596316
Clin Neuropsychol. 2019 Feb;33(2):200-208
pubmed: 30608020
Child Neuropsychol. 2018 Nov;24(8):999-1014
pubmed: 29017430
Lancet Haematol. 2019 Jun;6(6):e306-e316
pubmed: 31078468
Int J Radiat Oncol Biol Phys. 2015 Nov 15;93(4):882-91
pubmed: 26530758
Child Neuropsychol. 2020 Oct;26(7):881-899
pubmed: 32157961
Pediatr Res. 2021 Aug;90(2):419-426
pubmed: 33203967
Psychooncology. 2014 Jun;23(6):692-9
pubmed: 24497266
J Clin Oncol. 2013 Dec 10;31(35):4407-15
pubmed: 24190124
Blood. 2013 Jul 25;122(4):507-14
pubmed: 23741010
Child Neuropsychol. 2004 Mar;10(1):14-23
pubmed: 14977512
J Clin Oncol. 2019 Dec 10;37(35):3377-3391
pubmed: 31657981
N Engl J Med. 2009 Jun 25;360(26):2730-41
pubmed: 19553647
Eur J Cancer. 2003 Feb;39(3):359-65
pubmed: 12565989
J Clin Oncol. 2017 Aug 10;35(23):2700-2707
pubmed: 28671857
Cancer. 2010 May 15;116(10):2290-300
pubmed: 20209620
J Pediatr Psychol. 2012 May;37(4):458-66
pubmed: 22271791